Takeda announces planned divestiture of pharmaceutical assets to Hypera
MLex Summary: Takeda Pharmaceuticals has announced plans to divest its pharmaceutical assets to Hypera for $825 million in Latin America, according to a statement. The portfolio includes over-the-counter and prescription pharmaceutical products...To view the full article, register now.
Already a subscriber? Click here to view full article